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ABSTRACT
Background. The objective of this study was to compare
the effect of thoracic paravertebral block (TPVB) and local
anesthetic (LA) on persistent postoperative pain (PPP)
1 year following breast cancer surgery. Secondary objec-
tives were to compare the effect on arm morbidity and
quality of life.
Methods. Women scheduled for elective breast cancer
surgery were randomly assigned to either TPVB or LA
followed by general anesthesia. An NRS value of[3 at rest
or with movement 1 year following surgery defined PPP.
Blinded interim analysis suggested rates of PPP much
lower than anticipated, making detection of the specified
20 % absolute reduction in the primary outcome impossi-
ble. Recruitment was stopped, and all enrolled patients
were followed to 1 year.
Results. A total of 145 participants were recruited; 65
were randomized to TPVB and 64 to LA. Groups were
similar with respect to demographic and treatment char-
acteristics. Only 9 patients (8 %; 95 % CI 4–14 %) met
criteria for PPP 1 year following surgery; 5 were in the
TPVB and 4 in the LA group. Brief Pain Inventory severity
and interference scores were low in both groups. Arm
morbidity and quality of life were similar in both groups.
The 9 patients with PPP reported shoulder-arm morbidity
and reduced quality of life.
Conclusions. This study reports a low incidence of chronic
pain 1 year following major breast cancer surgery. Although
PPP was uncommon at 1 year, it had a large impact on the
affected patients’ arm morbidity and quality of life.
Breast cancer is the most common cancer among adult
women.1 Pain in the ipsilateral arm and shoulder persisting
6 months or more after surgical treatment has been repor-
ted in 25–60 % of women.2–5 The etiology of this pain is
multifactorial: The intercostobrachial nerve may be dam-
aged in 80–100 % of patients undergoing axillary lymph
node dissection (ALND), phantom and neuropathic pain
may result from injury to nerves that supply the breast and
axilla, and neuromas may form in scar tissue.2–4 Persistent
postoperative pain (PPP) causes both psychological distress
and disability in those affected.6,7 Reduced range of motion
of the shoulder, muscle weakness, and lymphedema are
also commonly reported.6–8
Multimodal analgesia strategies may reduce the inci-
dence of PPP.4,9 Thoracic paravertebral nerve block
(TPVB) and infiltration of local anesthetics (LA) at the
surgical site are 2 techniques shown to independently
reduce both short-term and long-term pain following breast
surgery.9–12 The comparative impact of these techniques on
PPP, arm morbidity, functional recovery, and quality of life
has not been explored.
The objective of this study was to compare the effect of
TPVB and LA on PPP 1 year following breast cancer
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surgery. We hypothesized that fewer women receiving
TPVB would report numeric pain scores [3 1 year fol-
lowing surgery than those receiving LA. Secondary
objectives of this study were to determine the effect of
TPVB and LA on arm morbidity and quality of life at
1 year.
METHODS
This randomized, controlled, double-blinded trial was
registered on ClinicalTrials.gov (NCT01089933) and
approved by The Ottawa Hospital Research Ethics Board
(Protocol 2006711-01H). It was conducted at The Ottawa
Hospital, a 900-bed, tertiary care academic health science
center affiliated with the University of Ottawa.
Population
Women [18 years of age with breast cancer scheduled
for elective breast conserving surgery with ALND, simple
mastectomy with sentinel lymph node biopsy (SLNB),
modified radical mastectomy (MRM), or ALND alone
were evaluated by research personnel for participation.
Exclusion criteria included ASA class 4 or 5, allergy to
study medications, contraindications to TPVB, consump-
tion of[20 mg of oral morphine or equivalent for[7 days,
creatinine clearance \40 ml/minute (calculated using the
Cockroft–Gault formula), preoperative radiation therapy or
\100 of shoulder abduction or flexion.
Randomization and Allocation Concealment
Eligible, consenting participants were allocated in par-
allel to TPVB and LA groups in a 1:1 ratio using computer-
generated random numbers. Randomization was blocked in
groups of 4–8 and stratified according to type of surgery.
Allocation to TPVB or LA group was printed on cards
placed in sealed, opaque, sequentially numbered envelopes.
Envelopes were opened immediately before surgery by the
attending anesthesiologist who prepared study medications.
Patients, surgeons, and study personnel remained blinded
to group allocation.
Preoperative Management
All patients received oral celecoxib 400 mg and acet-
aminophen 650 mg 2 h preoperatively. Participants
allocated to the TPVB group received nerve blocks at the
T1–T6 levels; 5 mL of 0.5 % ropivacaine with epinephrine
was injected at each space.13 Those allocated to the LA
group received subcutaneous injections of 0.9 % NaCl at
each level.
Intraoperative Management
A standardized general anesthetic using propofol, fen-
tanyl, dexamethasone, and volatile anesthetic gas was
given. At the conclusion of surgery, the surgeon infiltrated
the wound edges with 10 mL of study solution: 0.9 %
NaCl in the TPVB group or 0.5 % ropivacaine with epi-
nephrine in the LA group. After closure of the wound, a
further 20 ml of study solution was instilled through the
surgical drain, which was then clamped for 30 min.
Postoperative Management
Following discharge from hospital, patients received
oral acetaminophen 650 mg every 4 h for 48 h and cele-
coxib 200 mg every 12 h for 7 days in addition to their
standardized hydromorphone opioid prescription.
Outcome Assessments
All measures were compliant with the Initiative on
Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) and were performed before and 1 year
after surgery.14 Assessments were scheduled to not coin-
cide with chemotherapy or radiation therapy.
Primary Outcome Pain was assessed using an 11-point
numeric rating scale (NRS) with 0 representing ‘‘no pain’’
and 10 representing ‘‘pain as bad as you can imagine.’’ An
NRS value of [3 at rest or with movement 1 year
following surgery defined PPP.
Secondary Outcomes The Brief Pain Inventory (BPI)
quantified the intensity of pain using four 11-point NRS
scores that defined current, worst, least, and average pain
scores over the preceding 24 h.15 The BPI also assessed the
degree to which pain interferes with 7 daily activities using
11-point NRS scores anchored at 0 ‘‘does not interfere’’
and 10 ‘‘interferes completely.’’ Patients found to have PPP
were referred to the Ottawa Regional Cancer Centre Pain
and Symptom Management Clinic.
Flexion, extension, abduction, internal, and external
rotation of the shoulder was assessed in both shoulders with
a fixed scapula using a 12-in. universal goniometer. Rela-
tive shoulder movement, defined as ipsilateral movement/
contralateral movement 9 100, was assessed. A value of
\90 % was taken to indicate functional impairment.16
Measurements of arm circumference were made across the
metacarpal joint at the hand, at the radial styloid and every
10 cm proximal to that point. Relative arm circumference
was defined as ipsilateral circumference/contralateral cir-
cumference 9 100. A value of [110 % was taken to
indicate the presence of lymphedema.6 The Constant score
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quantifies overall disability of the arm and shoulder by
combining assessments of pain, activities of daily living,
range of motion, and power in a single metric with a
maximum score of 100.17 This score has been used in
breast cancer research and has well-defined reliability and
validity.18,19 Quality of life was assessed using the FACT-
B?4 and the SF-12 Health Survey (SF12).20,21 The FACT-
B?4 is a comprehensive, breast cancer specific question-
naire that incorporates 5 domains (concerns specific to
patients with breast cancer, and physical, social, emotional,
and functional well-being). The SF12 is a well-validated,
generic, measure of quality of life. Details of the surgery,
chemotherapy, and/or radiation therapy were recorded.
Sample Size Estimate
Previous research demonstrated that *25–60 % of
patients have pain 1 year following breast cancer sur-
gery.2–5 We took a midrange estimate of 40 % and
considered a 20 % absolute reduction in the prevalence of
pain as clinically important. Using a 2-sided test at the 5 %
level of significance, a sample of 82 patients per group
would yield 80 % power to detect a difference of this
magnitude. Anticipating a 10 % drop-out rate, we proposed
a final sample size of 91 per group.
Interim Analysis
In July 2011 the Data Safety Monitoring Board per-
formed an interim analysis of blinded, aggregate data. No
safety issues were identified among the 66 participants
enrolled to this point; however, only 7 participants (11 %,
95 % exact confidence limits 4.4–20.6 %) reported PPP
1 year following surgery. Detection of the specified 20 %
absolute reduction in the primary outcome was therefore
impossible. Thus, recruitment was stopped, and all enrolled
patients were followed to 1 year to provide an estimate of
the primary outcome and permit an exploration of sec-
ondary outcomes.
Statistics
Demographic characteristics were summarized for the
treatment and control group using means and standard
deviations for continuous measures (or medians and
interquartile ranges in the case of skewed distributions) and
frequencies and proportions for categorical measures. The
primary outcome (proportion of patients with arm pain
NRS [3 at rest or with arm movement at 1 year) was
analyzed using Fisher exact test. Continuous secondary
outcomes were assessed for normality and compared at
1 year using 2-sample t tests or 2-sample Wilcoxon tests,
while categorical outcomes were assessed using Pearson
Chi squared tests. SAS v 9.2 was used for all analyses. A 2-
sided 5 % level of significance was used for all statistical
tests.
RESULTS
Trial recruitment began December 6, 2007 with the last
measurement concluded September 28, 2012, A total of
145 participants were recruited; of these, 65 were ran-
domized to the TPVB group and 64 to the LA group.
Participant flow is documented in a CONSORT diagram
(Fig. 1).
The groups were similar with respect to demographic
and treatment characteristics (Table 1). The majority of
patients in both groups underwent MRM or simple mas-
tectomy with SNLB (Table 2). There were no surgical
complications that required reoperation. The majority of
patients in both groups received postoperative chemother-
apy and radiation therapy. The dosing and distribution of
radiation therapy and number of treatments were similar
between groups.
Chronic pain, arm disability, and quality of life data are
shown in Table 3. Only 9 patients (8 %; 95 % CI 4–14 %)
met criteria for PPP 1 year following surgery; 5 in the
TPVB group and 4 patients in the LA group. Since the trial
was not powered to detect differences in these outcomes,
FIG. 1 CONSORT diagram showing patient eligibility, enrollment,
randomization, and follow-up
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we focused on clinically important rather than statistically
significant differences between groups. Median BPI
severity and interference scores were low in both groups.
Both groups showed a small decline in Constant scores.
There were 6 patients in the TPVB group and 15 in the LA
group who had a 10 % relative increase in arm circum-
ference on the side of surgery, suggesting an overall 18 %
incidence of lymphedema. Although the absolute differ-
ence between groups was 15 % and statistically significant,
this result should be interpreted with caution: (1) multiple
testing increases the risk of spurious statistical significance,
and (2) the confidence interval around the difference is
relatively wide (95 % CI 1.2–28.1 %). Shoulder range of
motion (ROM), FACT-B?4, and SF-12 Mental (MCS) and
Physical (PCS) Component scores were comparable in both
groups.
Characteristics of the 9 patients with chronic pain at
1 year are shown in Table 4. These patients had a median
of 14 (IQR, 7.0–19.0) lymph nodes removed, and 3 patients
(33 %) had their intercostobrachial nerve preserved.
Lymphedema was common as was a large decrease in the
Constant score in the ipsilateral arm. Lowered quality of
life was reflected in FACT-B?4 and SF-12 PCS scores.
Despite pain and swelling, ROM of both arms was pre-
served and no patient required opioid analgesia.
DISCUSSION
Incidence of Persistent Postoperative Pain
Only 8 % of women in this trial reported PPP 1 year
following major breast cancer surgery; much lower than
the 25–60 % reported in the literature. Because of the
surprisingly low incidence of PPP, we were unable to
compare the efficacy of TPVB and LA. Possible explana-
tions for this discrepancy are: study design, perioperative
surgical care, perioperative anesthesia care, and definition
of PPP. The majority of studies on PPP following breast
surgery are conducted retrospectively via questionnaire,
*2–2.5 years and up to 3.5–4 years following sur-
gery.5,22–25 The retrospective questionnaire study design
and long duration since the inciting event, increase the
possibility of error. In contrast, patients in our study were
TABLE 1 Preoperative patient characteristics (mean, SD)
Characteristic TPVB (N = 65) LA (N = 64)
Age 54 (10.8) 56 (10.6)
BMI 28.4 (6.5) 29.0 (5.2)
ASA
1 11 (17 %) 3 (5 %)
2 36 (55 %) 42 (65 %)
3 18 (28 %) 19 (30 %)
Neoadjuvant hormonal therapy 4 (6 %) 4 (6 %)
Neoadjuvant chemotherapy 14 (22 %) 10 (16 %)
Medical comorbidities 31 (48 %) 23 (36 %)
Fibromyalgia 2 (3 %) 0 (0 %)
Anxiety disorder 3 (5 %) 2 (3 %)
Depression 2 (3 %) 3 (5 %)
Diabetes mellitus 7 (11 %) 8 (13 %)
Hypertension 21 (32 %) 20 (31 %)
Peripheral vascular disease 1 (2 %) 0 (0 %)
Hypercholesterolemia 7 (11 %) 5 (8 %)
Stroke/TIA 0 (0 %) 0 (0 %)
Small vessel vasculitis 1 (2 %) 0 (0 %)
Smoker 8 (13 %) 7 (12 %)
Constant score
Ipsilateral arm 85.47 (9.18) 87.70 (7.37)
Contralateral arm 87.60 (8.28) 88.87 (6.02)
SF-12 MCS 45.62 (11.16) 47.74 (9.69)
SF-12 PCS 52.54 (10.76) 51.60 (8.57)
BMI body mass index, ASA American Society of Anesthesiologist,
TIA transient ischemic attack
TABLE 2 Patient surgical and postoperative treatment variables











9 (14 %) 6 (9 %)
MRM or Simple
mastectomy ? SLNB
54 (83 %) 58 (91 %)
ALND alone 2 (3 %) 0 (0 %)
Number lymph nodes
removed
7 (3, 13) 9.5 (4.5, 19) 0.040
Intercostobrachial
nerve preserved








37 (57 %) 42 (66 %) 0.310
Total dose 48.1 (2.90) 49.0 (2.00) 0.193
Total dose per fraction 2.09 (0.20) 2.04 (0.11) 0.192
Site of radiation
Breast or chest wall 37 (57 %) 42 (66 %) 0.310
Breast or chest wall ?
lymph nodes
31 (48 %) 38 (59 %) 0.184
ALND axillary lymph node dissection, SLNB sentinel lymph node
biopsy, MRM modified radical mastectomy
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prospectively assessed by a trained nurse at each follow-up
visit.
Intercostobrachial neuralgia is a recognized etiology of
chronic pain following breast cancer surgery.2 It has been
recommended that for optimal quality of cancer care, ‘‘not
only treatment of tumours with a low incidence but also
other complex or high risk cancer procedures should be
provided in a specialized setting, with the right infra-
structure, sufficient volume and adequate expertise.’’26 All
surgeons involved in this study have subspecialized prac-
tices focusing on breast cancer surgery. Although no
studies have been done to directly examine the relationship
between surgical expertise and pain outcomes, Kehlet27
suggests that ‘‘nerve injury might be reduced by surgical
expertise,’’ thus reducing the risk of PPP. Indeed in the
majority of our patients, the intercostobrachial nerve was
identified and preserved. The median number of lymph
nodes removed in our study is on the lower end of the range
reported by Olaya et al.28 who examined the number of
nodes removed in current surgical practice. These authors
noted that ‘‘increased breast surgery practice is associated
with a decreased number of (nodes) removed.’’ Since there
is a proportional relationship between the number of lymph
nodes removed and the occurrence of PPP following breast
cancer surgery, the low number of nodes removed is in
keeping with our speculation that surgical factors in our
study may have contributed toward improved pain
outcomes.29
The intensity of acute postoperative pain has been
identified as a predisposing risk factor to the development
of PPP.23,30,31 The anesthetic techniques used in this study
incorporated multimodal, procedure-specific techniques
designed to minimize postoperative pain. Both TPVB and
LA infiltration have been shown to provide superior anal-
gesia in breast surgery compared with opioid medications
alone.4,9 Mitchell et al.32 showed that co-analgesics acet-
aminophen ? ibuprofen were as effective as Tylenol 3 in
treating pain in breast cancer patients. We preemptively
treated and postoperatively prescribed to patients a long (7-
day) course of co-analgesic medications that have been
shown to contribute to improved postoperative analgesia.33
The synergism of multimodal pain regimens using TPVB
or LA infiltration, in combination with effective co-anal-
gesics and meticulous surgical practices, likely contributed
to our low incidence of PPP.
There is no agreement in the literature on the definition
of PPP; many studies use subjective definitions.34 Grigoras
et al.35 prospectively studied 36 breast cancer patients
receiving perioperative intravenous lidocaine versus pla-
cebo and found an overall 3-month incidence of PPP of
31 %; however, they subjectively defined PPP as an affir-
mative answer to ‘‘Have you had pain in the last week
which you attribute to your breast surgery?’’. Fabro et al.29
reported prospective data collected 6 months following
breast cancer surgery and found a 52 % incidence of pain.
These investigators also defined pain subjectively using
reports of hyperesthesia and percussion tenderness. Neither
author used established and validated measurement tools to
evaluate for the presence of pain. We used multiple, robust
measures of pain intensity in our study and considered it
important to use a meaningful definition of PPP that has
functional significance to the patient. A NRS [3 signifies
pain that impacts a patient’s mood and activity and is a
reliable, well established definition of clinically relevant
moderate to severe pain in cancer patients.36–38 Our
patients’ low BPI pain severity scores and low interference
scores corroborate our low rate of PPP.37,38
TABLE 3 Summary of primary and secondary outcomes by groups
at 1 year (median, IQR) and (mean, SD)
Assessment tool TPVB (N = 58) LA (N = 60) P
value
Primary outcome
Chronic pain 5 (9 %) 4 (7 %) 0.741
Secondary outcome
BPI pain severity 0.125 (0–2.25) 0.25 (0–1.50) 0.989
Pain interference 0 (0–1) 0 (0–0.86) 0.744

















6.06 (9.86) 4.62 (9.28) 0.417
SF-12 PCS (change
from baseline)
-4.66 (12.96) -4.83 (9.22) 0.934





160 (150, 160) 160 (140, 160) 0.388
Ipsilateral arm—
degrees abduction
160 (155, 160) 160 (147.5, 160) 0.485
Contralateral arm—
degrees forward
160 (160, 160) 160 (159.5, 160) 0.324
Contralateral arm—
degrees abduction
160 (160, 160) 160 (154, 160) 0.612
SF-12 MCS SF-12 mental component summary, SF-12 PCS SF-12
physical component summary
a Only recorded postoperatively
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Arm Morbidity and Quality of Life
Patients in our study showed impairments in ROM
classified as ‘‘mild’’ when compared with age and gender
norms39 Our 18 % overall incidence of lymphedema is
comparable to that reported in the literature as are our
patients’ SF-12 and FACT-B?4 scores.40–42 It should be
noted, however, Constant scores were reduced, lymphe-
dema was more common, and quality of life was poor
among the 9 women with PPP. Indeed, their 1-year SF-12
PCS was similar to that reported by patients with chronic
heart, lung, and kidney disease and their FACT-B?4 scores
were lower than those reported in the ALMANAC study,
indicating a severe, disease-specific burden of illness.42,43
Clearly PPP is a significant problem for those affected.
Study Limitations
Our study was stopped early following interim analysis.
Expanding to a multicenter study may have allowed for
increased patient recruitment. Because of our low inci-
dence of PPP, we had insufficient events to allow for
identification of predictors for PPP.
CONCLUSIONS
This prospective study reports an 8 % incidence of PPP
1 year following major breast cancer surgery with lymph
node resection. Our patients experienced minor declines in
arm function, and quality of life did not diminish. Patients
can be reassured that experienced surgical teams dedicated
to breast oncology who use multimodal analgesic therapies
may achieve low rates of PPP and preserve both activity
and quality of life 1-year following breast surgery.
Although PPP was not frequent at 1 year, it did have a
large impact on the affected patients’ arm morbidity and
quality of life. Future avenues of research should continue
to focus on ways to reduce and treat PPP and arm mor-
bidity in women undergoing breast cancer surgery.
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